Mouse Monoclonal LEF1 Antibody

+ +

•  

   
     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

•  

   
     Immunohistochemical analysis of paraffin-embedded human HeLa tissues using LEF1 mouse mAb with DAB staining.    

The LEF1 (Lymphoid Enhancer-Binding Factor 1) antibody is a crucial tool for studying the role of the LEF1 protein, a transcription factor belonging to the T-cell factor/lymphoid enhancer factor (TCF/LEF) family. LEF1 is a key mediator of the Wnt/β-catenin signaling pathway, which regulates embryonic development, cell proliferation, and differentiation. Structurally, LEF1 contains a high-mobility group (HMG) DNA-binding domain that facilitates its interaction with β-catenin, enabling the activation of Wnt target genes such as Cyclin D1 and c-Myc. Dysregulation of LEF1 is implicated in various cancers, including colorectal carcinoma, leukemia, and skin tumors, where it often drives tumor progression and metastasis.

LEF1 antibodies are widely used in research to detect LEF1 expression and localization via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). They help elucidate LEF1's role in normal physiology, such as lymphopoiesis and hair follicle development, and its pathological contributions to oncogenesis. Commercially available LEF1 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes or post-translational modifications. Validation for specificity and cross-reactivity is critical, as LEF1 shares homology with other TCF/LEF family members. In diagnostics, LEF1 antibodies aid in distinguishing certain malignancies, such as basal cell carcinoma from other skin tumors. Ongoing research continues to explore LEF1 as a therapeutic target, underscoring the antibody's importance in both basic and translational studies.